Gestational diabetes mellitus (GDM) is a common pregnancy complication associated with adverse maternal and fetal outcomes, including macrosomia, preterm birth, preeclampsia, and increased future diabetes risk. Myo-inositol, an insulin-sensitizing nutrient, has shown promise in prior studies for reducing GDM incidence in high-risk groups (e.g., those with family history of type 2 diabetes, obesity, or PCOS). This pilot trial, titled “Myo-Inositol for the Prevention of Gestational Diabetes Mellitus (MiGDM),” was designed as a randomized, double-blind, placebo-controlled study to preliminarily evaluate myo-inositol supplementation’s effects on GDM prevention and broader fetal/maternal outcomes.
Endometrial cancer (EC), particularly the endometrioid subtype, remains a leading gynecologic malignancy with limited options for advanced, ER-positive disease. Preclinical models demonstrate synergistic antitumor effects from concurrent inhibition of estrogen receptor (ER), cyclin-dependent kinase 4/6 (CDK4/6), and phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathways. Building on window-of-opportunity studies showing metformin’s suppression of PI3K/mTOR signaling in EC, we conducted a single-arm, non-randomized phase 2 trial (NCT03675893) to evaluate the combination of letrozole (an aromatase inhibitor), abemaciclib (a CDK4/6 inhibitor), and metformin (a PI3K/mTOR modulator) in patients with ER-positive endometrioid EC.
On October 24, 2025, the U.S. Food and Drug Administration (FDA) approved Lynkuet™ (elinzanetant), developed by Bayer, as the first dual neurokinin (NK) targeted therapy—a combined NK1 and NK3 receptor antagonist—for the treatment of moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, due to menopause. This non-hormonal, once-daily oral therapy addresses a major unmet need in menopausal care, where VMS affect daily functioning, sleep, and quality of life and are a primary reason women seek medical intervention.
